Anika Therapeutics (ANIK) Current Assets (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Current Assets data on file, last reported at $93.6 million in Q1 2026.

• Current Assets for Q1 2026 came in at $93.6 million, down 8.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $93.6 million (down 8.73% YoY), and the FY2025 annual result was $103.4 million, down 9.06% from the prior year.
• Current Assets eased to $93.6 million in Q1 2026 per ANIK's latest filing, from $103.4 million in the prior quarter.
• Over five years, Current Assets peaked at $169.5 million in Q4 2022 and troughed at $93.6 million in Q1 2026.
• A 5-year average of $139.2 million and a median of $155.0 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets grew 1.84% in 2024, then slumped 35.92% in 2025.
• A 5-year view of Current Assets shows it stood at $169.5 million in 2022, then fell by 3.68% to $163.3 million in 2023, then plunged by 30.41% to $113.7 million in 2024, then dropped by 9.06% to $103.4 million in 2025, then declined by 9.48% to $93.6 million in 2026.
• Business Quant data shows ANIK's Current Assets at $93.6 million in Q1 2026, $103.4 million in Q4 2025, and $101.6 million in Q3 2025.